Vanda Pharmaceuticals (VNDA) Gross Profit (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted Gross Profit of $48.6 million for Q1 2026, down 9.04% sequentially from $53.4 million in Q4 2025, and up 4.38% YoY from $46.5 million in Q1 2025.
Vanda Pharmaceuticals (VNDA) Gross Profit (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Gross Profit for 14 years, with the latest figure at $48.6 million in Q1 2026.
- Quarterly Gross Profit rose 4.38% year-over-year to $48.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $205.1 million (up 7.97% YoY) and the FY2025 annual result came in at $203.1 million, up 8.32% from the prior year.
- Gross Profit retreated to $48.6 million in Q1 2026 per VNDA's latest filing, from $53.4 million in the prior quarter.
- Over five years, Gross Profit peaked at $59.0 million in Q3 2022 and troughed at $35.8 million in Q3 2023.
- A 5-year average of $49.8 million and a median of $49.9 million in 2025 frame the typical range for Gross Profit.
- The sharpest annual moves came in 2023 and 2024: Gross Profit tumbled 39.4% in 2023, then gained 26.15% in 2024.
- Over 5 years, Gross Profit stood at $58.2 million in 2022, then declined by 28.21% to $41.8 million in 2023, then advanced by 21.01% to $50.6 million in 2024, then climbed by 5.51% to $53.4 million in 2025, then decreased by 9.04% to $48.6 million in 2026.
- According to Business Quant data, Gross Profit over the past three periods registered $48.6 million, $53.4 million, and $53.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.97 Mn |
| Jun 30, 2026 | 46.97 Mn |
| Mar 31, 2026 | 48.56 Mn |
| Mar 31, 2026 | 48.56 Mn |
| Dec 31, 2025 | 53.38 Mn |
| Dec 31, 2025 | 53.38 Mn |
| Sep 30, 2025 | 53.30 Mn |
| Sep 30, 2025 | 53.30 Mn |
| Jun 30, 2025 | 49.85 Mn |
| Jun 30, 2025 | 49.85 Mn |
| Mar 31, 2025 | 46.52 Mn |
| Mar 31, 2025 | 46.52 Mn |
| Dec 31, 2024 | 50.60 Mn |
| Dec 31, 2024 | 50.60 Mn |
| Sep 30, 2024 | 45.10 Mn |
| Sep 30, 2024 | 45.10 Mn |
| Jun 30, 2024 | 47.74 Mn |
| Jun 30, 2024 | 47.74 Mn |
| Mar 31, 2024 | 44.02 Mn |
| Mar 31, 2024 | 44.02 Mn |